With a $2.437 million grant from the Sohn Conference Foundation, NYGC and its founding members — Columbia University, Memorial Sloan Kettering Cancer Center, New York University School of Medicine, Rockefeller University, and Weill Cornell Medical College — will apply their collective knowledge and technology to explore why some tumors in children respond readily to treatment while others do not, or do so only temporarily. NYGC will conduct the genome sequencing and computational analysis for the effort, with a focus on "outlier" tumors that respond particularly well or poorly to treatment.
Childhood leukemia is the most common form of cancer among children and teens, while neuroblastoma, a malignant tumor that develops from nerve tissue, is the most common cause of cancer diagnosed in the first year of life, a finding which suggests it has strong genetic roots.
"The Sohn Conference Foundation is proud to support this first-of-its-kind collaboration for pediatric cancer research in New York City," said Evan Sohn, founder of the Sohn Conference Foundation. "We are investing in some of the best scientists in the world, as they come together to solve our shared challenge to end childhood cancer. We have every confidence that the force of their great minds as applied to genomics will unleash discoveries of a new order."